# NRX Pharmaceuticals, Inc.: overview NRXP · Nasdaq · CIK 1719406 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/nrxp.md) · [Financials](/companies/nrxp/financials.md) · [Filings](/companies/nrxp/filings.md) · [Insiders](/companies/nrxp/insiders.md) Latest reported revenue: [$1.1m](/filings/0001437749-26-028027.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-028027). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0001437749-25-035210.md) | [0.0 d](/filings/0001437749-26-009418.md) | [0.0](/filings/0001437749-26-017397.md) | [0.0](/filings/0001437749-26-028027.md) | [242](/filings/0001437749-25-035210.md) | [983 d](/filings/0001437749-26-009418.md) | [1,068](/filings/0001437749-26-017397.md) | [1,101](/filings/0001437749-26-028027.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | [(1662.8%)](/filings/0001437749-25-035210.md) | [(470.4%) d](/filings/0001437749-26-009418.md) | [(444.0%)](/filings/0001437749-26-017397.md) | [(590.8%)](/filings/0001437749-26-028027.md) | | Net margin | % | not reported | not reported | not reported | not reported | [(2433.9%)](/filings/0001437749-25-035210.md) | [36.6% d](/filings/0001437749-26-009418.md) | [(133.9%)](/filings/0001437749-26-028027.md) | [(1500.5%)](/filings/0001437749-26-028027.md) | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $k | [(2,306) d](/filings/0001437749-25-035210.md) | [(2,098) d](/filings/0001437749-26-009418.md) | [(3,480)](/filings/0001437749-26-017397.md) | [(4,028) d](/filings/0001437749-26-028027.md) | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [0.0](/filings/0001437749-25-007743.md) | [0.0](/filings/0001437749-26-009418.md) | [1.2](/filings/0001437749-26-009418.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | [(1324.4%)](/filings/0001437749-26-009418.md) | | Net margin | % | not reported | not reported | not reported | not reported | [(2336.5%)](/filings/0001437749-26-009418.md) | | Diluted EPS | $ per share | [(1.98)](/filings/0001558370-23-005292.md) | [(0.60)](/filings/0001558370-23-005292.md) | not reported | not reported | not reported | | Free cash flow | $m | [(37.7)](/filings/0001558370-23-005292.md) | [(39.8)](/filings/0001558370-24-004396.md) | [(21.7)](/filings/0001437749-25-007743.md) | [(10.6)](/filings/0001437749-26-009418.md) | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nrxp/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [B Group, Inc.](/funds/2043476.md) | 2026-06-30 | $16.7m | 4,091,767 | | Added +1,091,767 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $6.6m | 1,618,159 | | Added +457,975 | | [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $3.8m | 928,728 | | New +928,728 | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $3.7m | 893,864 | | New +893,864 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $2.8m | 680,043 | | New +680,043 | | [AdvisorShares Investments LLC](/funds/1425930.md) | 2026-06-30 | $2.7m | 659,018 | | Added +238,551 | | [COMMONWEALTH EQUITY SERVICES, LLC](/funds/312272.md) | 2026-06-30 | $1.9m | 454,418 | | Added +56,987 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $1.7m | 423,115 | | Added +397,888 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.3m | 314,659 | | Added +4,547 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $927.6k | 226,800 | Call | Added +157,100 | ## Recent filings [All 474 filings](/companies/nrxp/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-16 | 21:16 ET | [8-K](/filings/0001437749-26-032828.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-032828 | | 2026-10-05 | 21:00 ET | [8-K](/filings/0001437749-26-032042.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001437749-26-032042 | | 2026-09-16 | 01:17 ET | [8-K](/filings/0001437749-26-030492.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-030492 | | 2026-09-14 | 12:00 ET | [8-K](/filings/0001437749-26-030228.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-030228 | | 2026-08-17 | 12:00 ET | [8-K](/filings/0001437749-26-028111.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-028111 | | 2026-08-14 | 20:32 ET | [10-Q](/filings/0001437749-26-028027.md) | Quarterly report, period 2026-06-30 | 0001437749-26-028027 | | 2026-08-07 | 11:00 ET | [8-K](/filings/0001437749-26-026428.md) | 7.01 Regulation FD disclosure | 0001437749-26-026428 | | 2026-07-22 | 11:00 ET | [8-K](/filings/0001437749-26-024037.md) | 8.01 Other events | 0001437749-26-024037 | | 2026-06-04 | 21:20 ET | [8-K](/filings/0001437749-26-019576.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-019576 | | 2026-06-02 | 21:30 ET | [8-K](/filings/0001437749-26-019196.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-019196 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-009418.md), filed Mar 23, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e7f54b98-7657-4d49-bc31-82c14b830f32) ## About the filer - CIK: 1719406 - Tickers: NRXP - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.